Skip to main content

Daniel Kelly Benjamin, MD, PhD

Kiser-Arena Distinguished Professor of Pediatrics
Professor of Pediatrics
Member in the Duke Clinical Research Institute
Campus mail: 7044 Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27710
Phone: (919) 668-7081

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 50 of the most commonly used medicines in children. Each of these trials is conducted under an investigational new drug (IND) application with guidance from the Food and Drug Administration for labeling.

Signature programs of the Network include clinical trials in premature, term infants and most recently, obese children. Over the past 10 years, Dr. Benjamin’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Dr. Benjamin is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Dr. Benjamin’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows (including two T32 programs sponsored by NIH for which he is PI), and multiple junior faculty.

Dr. Benjamin has published over 250 works with up to 7000 citations. 

Education and Training

  • Fellow, Pediatric Infectious Diseases, Pediatrics, Duke University, 1998 - 2001
  • Resident, Pediatrics, Children's Hospital, 1995 - 1998
  • Ph.D., University of North Carolina at Chapel Hill, 2003
  • M.P.H., University of North Carolina at Chapel Hill, 2001
  • M.D., University of Virginia, 1995

Selected Grants and Awards

Publications

Gonzalez, Daniel, Laura P. James, Amira Al-Uzri, Miroslava Bosheva, Felice C. Adler-Shohet, Susan R. Mendley, John S. Bradley, et al. “Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents.” Antimicrob Agents Chemother 62, no. 8 (August 2018). https://doi.org/10.1128/AAC.00692-18.

Full Text

Kovanda, Laura L., Thomas J. Walsh, Daniel K. Benjamin, Antonio Arrieta, David A. Kaufman, P Brian Smith, Paolo Manzoni, et al. “Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.” Pediatr Infect Dis J 37, no. 6 (June 2018): 580–85. https://doi.org/10.1097/INF.0000000000001957.

Full Text

Smith, Brian, Susan Knox, and Daniel K. Benjamin. “Coordination of the Environmental influences on Child Health Outcomes program: so the whole is greater than the sum of its parts.” Curr Opin Pediatr 30, no. 2 (April 2018): 263–68. https://doi.org/10.1097/MOP.0000000000000598.

Full Text

Corneli, Amy, Chris Wheeler, John Bradley, Breck Gamel, Sumathi Nambiar, Gary J. Noel, Li Lin, Jamie N. Roberts, and Daniel K. Benjamin. “Facilitators and barriers to the successful implementation of pediatric antibacterial drug trials: Findings from CTTI's survey of investigators.” Contemp Clin Trials Commun 9 (March 2018): 115–20. https://doi.org/10.1016/j.conctc.2018.01.003.

Full Text

Greenberg, Rachel G., Breck Gamel, Diane Bloom, John Bradley, Hasan S. Jafri, Denise Hinton, Sumathi Nambiar, et al. “Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative.” Contemp Clin Trials Commun 9 (March 2018): 33–39. https://doi.org/10.1016/j.conctc.2017.11.005.

Full Text

Greenberg, Rachel G., Amy Corneli, John Bradley, John Farley, Hasan S. Jafri, Li Lin, Sumathi Nambiar, et al. “Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: Findings from the Clinical Trials Transformation Initiative.” Contemp Clin Trials Commun 9 (March 2018): 7–12. https://doi.org/10.1016/j.conctc.2017.11.006.

Full Text

Le, Jennifer, Brenda Poindexter, Janice E. Sullivan, Matthew Laughon, Paula Delmore, Martha Blackford, Ram Yogev, et al. “Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates.” Ther Drug Monit 40, no. 1 (February 2018): 103–8. https://doi.org/10.1097/FTD.0000000000000466.

Full Text

Testoni, Daniela, Christoph P. Hornik, Ruth Guinsburg, Reese H. Clark, Rachel G. Greenberg, Daniel K. Benjamin, and P Brian Smith. “Early lumbar puncture and risk of intraventricular hemorrhage in very low birth weight infants.” Early Hum Dev 117 (February 2018): 1–6. https://doi.org/10.1016/j.earlhumdev.2017.11.013.

Full Text

Shakhnovich, Valentina, P Brian Smith, Jeffrey T. Guptill, Laura P. James, David N. Collier, Huali Wu, Chad E. Livingston, Jian Zhao, Gregory L. Kearns, and Gregory L. Best Pharmaceuticals for Children Act – Pediatric Trials Network. “Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.” J Pediatr 193 (February 2018): 102-108.e1. https://doi.org/10.1016/j.jpeds.2017.10.011.

Full Text

Watt, Kevin M., Debbie Avant, Jennifer Sherwin, Daniel K. Benjamin, Christoph Hornik, Jennifer S. Li, and P Brian Smith. “Effect of renal function on antihypertensive drug safety and efficacy in children.” Pediatr Nephrol 33, no. 1 (January 2018): 139–46. https://doi.org/10.1007/s00467-017-3763-8.

Full Text

Pages